TriSalus Life Sciences (TLSIW) Return on Capital Employed (2021 - 2026)

TriSalus Life Sciences has reported Return on Capital Employed for 6 years, with the latest figure at 67.75% in Q1 2026.

• For the quarter ending Q1 2026, Return on Capital Employed rose 15103.0% year-over-year to 67.75%; the trailing twelve-month figure through Mar 2026 stood at 67.75% (up 15103.0% YoY), and the FY2025 full-year result was 148.45%, up 10884.0% from the prior year.
• Return on Capital Employed for Q1 2026 stood at 67.75%, up from 110.44% in the prior quarter.
• The five-year high for Return on Capital Employed was 1.17% in Q2 2022, with the low at 817.14% in Q1 2024.
• Historically, Return on Capital Employed has averaged 215.54% across 5 years, with a median of 182.56% in 2023.
• Annual changes were most pronounced in 2024 — Return on Capital Employed sank 63458 bps — and 2025, when it jumped 59836 bps.
• TriSalus Life Sciences' Return on Capital Employed stood at 19.98% in 2022, then tumbled by 1793 bps to 378.2% in 2023, then jumped by 38 bps to 233.38% in 2024, then jumped by 53 bps to 110.44% in 2025, then surged by 39 bps to 67.75% in 2026.
• The last three Return on Capital Employed figures came in at 67.75% (Q1 2026), 110.44% (Q4 2025), and 111.7% (Q3 2025), per Business Quant data.